The aim of the Proof of Concept project, whose main researcher is RNDr. Jan Balvan, Ph.D. from the Department of Pathophysiology of the Faculty of Medicine of Masaryk University and which was supported this year within the TA CR GAMA 2 programme, is the development of a robust method enabling automatic detection and resolution of cell death subtypes based on their phase dynamics captured by holographic microscopy. This method has a high potential for cytotoxicity and biocompatibility testing in the development of new drugs and materials. You can find the interview with Dr. Balvan here.
Analysis of epidemiological situations
In 2020, the Proof of Concept project of prof. RNDr. Ladislav Dušek, Ph.D. from the Institute of Biostatistics and Analyses called Online platform for real-time monitoring, analysis and management of epidemic situations. The output is a web application Monitoring, analysis and management of epidemic situations (MAMES, https://mames.iba.muni.cz). It enables the general public to model the development of the COVID-19 epidemic in real time and thus responds to the current need for the rapid availability of adequate information related to the spread of the disease.
Development of oncological drugs
An intensive programme of development of oncological drugs based on the know-how co-developed by LF MU under a license agreement with Artios Pharma Ltd. is underway. The research is focused on inhibition of nucleases by patented compounds developed in the laboratories of the scientific teams of doc. Kamil Paruch and doc. Lumír Krejčí from the Faculty of Science and Faculty of Medicine of MU. Artios Pharma Ltd. announced a three-year research collaboration with Merck KGaA in 2020 to discover and develop several new cancer drugs.
Evaluation of the effect of stress
Under the leadership of prof. MUDr. Julie Dobrovolná, Ph.D., a new MU spin-off company called Entrant s.r.o. was established, focused on the evaluation of the impact of stress on humans in various situations, especially in fields where stress plays a key role. The device that will be developed may help soldiers, pilots and astronauts in the future. The technology received the support of the space incubator ESA.BIC Brno.
In vitro system for preclinical embryotoxicity testing
Within the framework of the TA ČR project GAMA 2 Proof of Concept by PharmDr. Zuzana Holubcová, Ph.D. (from the Institute of Histology and Emryology, Faculty of Medicine, Masaryk University) called MUNI-BLAST, an in-vitro system based on 3D structures resembling human embryos at the blastocyst stage (so-called blastoids) will be developed and tested, which has the potential to eliminate false-negative results and the need to use a large number of laboratory animals.
New biotechnology for milk production
The technology of milk production in mammary gland organoids will be verified and upscaled within the Proof of Concept project by Mgr. Zuzana Koledová, Ph.D. from the Institute of Histology and Emryology, Faculty of Medicine, Masaryk University. The MUNI-MILK project was supported by the TA ČR GAMA 2 programme. The technology targets the new, emerging market of food created by biotechnology.
All activities in this field were implemented with the support of the Technology Transfer Office.
💡 Outputs in 2021
Trademark "Mindfulness Research and Practice Network of Masaryk University", registration number 387246
trademark "Trýb's Dermatology Day", registration number 387926.
1 granted European patent EP3556755 for the invention entitled "Substituted aminothiazoles as inhibitors of nucleases"
Patent EP3380508B1 entitled "Thermostable FGF2 polypeptide, use thereof and culture medium containing thermostable FGF2", which is commercialized by Enantis Ltd. and the Faculty of Medicine have a significant co-inventor interest in this invention, was the subject of several license agreements during 2021.
💡 Outputs in 2020
EP3380508B1 entitled "Thermostable FGF2 polypeptide, use thereof and culture medium containing thermostable FGF2". The patent is commercialized by Enantis s.r.o.
EP3437692B1 entitled "Method for prediction of clinical response to VNS therapy in epileptic patients". A multicentre clinical study is being prepared in cooperation with CZECRIN / ECRIN.
EP3556756B1 entitled "Substituted propanamides as inhibitors of nucleases". The patent is part of the intellectual property licensed to Artios Pharma Ltd.
Utility Model No. 33677 entered in the Register of Utility Models of the Industrial Property Office entitled "Kit for testing the effect of phage preparations".